Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The Microbe Directory: An annotated, searchable inventory of microbes' characteristics.

Shaaban H, Westfall DA, Mohammad R, Danko D, Bezdan D, Afshinnekoo E, Segata N, Mason CE.

Gates Open Res. 2018 Jan 5;2:3. doi: 10.12688/gatesopenres.12772.1.

2.

The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.

Novakovic T, Martin AP, Parker M, Ferrario A, Vukovic S, Łanda K, Duba J, Dankó D, Kotsopoulos N, Godman B, Ristic J, Stefanovic D, Tesic D.

Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):519-521. doi: 10.1080/14737167.2017.1385394. Epub 2017 Oct 9.

PMID:
28946800
3.

Comprehensive benchmarking and ensemble approaches for metagenomic classifiers.

McIntyre ABR, Ounit R, Afshinnekoo E, Prill RJ, Hénaff E, Alexander N, Minot SS, Danko D, Foox J, Ahsanuddin S, Tighe S, Hasan NA, Subramanian P, Moffat K, Levy S, Lonardi S, Greenfield N, Colwell RR, Rosen GL, Mason CE.

Genome Biol. 2017 Sep 21;18(1):182. doi: 10.1186/s13059-017-1299-7.

4.

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.

Ferrario A, Arāja D, Bochenek T, Čatić T, Dankó D, Dimitrova M, Fürst J, Greičiūtė-Kuprijanov I, Hoxha I, Jakupi A, Laidmäe E, Löblová O, Mardare I, Markovic-Pekovic V, Meshkov D, Novakovic T, Petrova G, Pomorski M, Tomek D, Voncina L, Haycox A, Kanavos P, Vella Bonanno P, Godman B.

Pharmacoeconomics. 2017 Dec;35(12):1271-1285. doi: 10.1007/s40273-017-0559-4.

5.

Balanced assessment systems revisited.

Dankó D, Molnár MP.

J Mark Access Health Policy. 2017 Jul 26;5(1):1355190. doi: 10.1080/20016689.2017.1355190. eCollection 2017.

6.

Entropy-scaling search of massive biological data.

Yu YW, Daniels NM, Danko DC, Berger B.

Cell Syst. 2015 Aug 26;1(2):130-140.

7.

Health technology assessment in the Balkans: opportunities for a balanced drug assessment system.

Dankó D, Petrova G.

Biotechnol Biotechnol Equip. 2014 Nov 2;28(6):1181-1189. Epub 2014 Nov 26.

8.

Comparison of NITAG policies and working processes in selected developed countries.

Ricciardi GW, Toumi M, Weil-Olivier C, Ruitenberg EJ, Dankó D, Duru G, Picazo J, Zöllner Y, Poland G, Drummond M.

Vaccine. 2015 Jan 1;33(1):3-11. doi: 10.1016/j.vaccine.2014.09.023. Epub 2014 Sep 23.

9.

Health technology assessment in middle-income countries: recommendations for a balanced assessment system.

Dankó D.

J Mark Access Health Policy. 2014 Mar 11;2. doi: 10.3402/jmahp.v2.23181. eCollection 2014. Review.

10.

[Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention].

Acs N, Bata Z, Danko D, Hernádi Z, Kálmán M, Kornya L, Kovács J, Mézáros G, Molnár MP, Mór Z, Novák Z, Sobel G, Szentirmay Z, Takács L, Tisza T.

Orv Hetil. 2012 Dec;153 Suppl:3-38. Review. Hungarian. No abstract available.

PMID:
23687666
11.

A humán papillomavírus okozta megbetegedések, megelőzésük lehetőségei és ennek népegészségügyi előnyei.

Kásler M, Ács N, Bata Z, Dankó D, Hernádi Z, Kálmán M, Kornya L, Kovács J, Mészáros G, Molnár MP, Mór Z, Novák Z, Sobel G, Szentirmay Z, Takács L, Tisza T.

Orv Hetil. 2012 Dec 15;153 Suppl 4:1-39. doi: 10.1556/650.2012.0004. Hungarian. No abstract available.

PMID:
26686555
12.

[Special considerations in generic substitution of immunosuppressive drugs in transplantation].

Remport A, Dankó D, Gerlei Z, Czebe K, Kiss I.

Orv Hetil. 2012 Aug 26;153(34):1341-9. doi: 10.1556/OH.2012.29429. Review. Hungarian.

PMID:
22913916
13.

Supplemental Content

Support Center